| 000 | 01906 a2200577 4500 | ||
|---|---|---|---|
| 005 | 20250515002349.0 | ||
| 264 | 0 | _c20051110 | |
| 008 | 200511s 0 0 eng d | ||
| 022 | _a1528-4336 | ||
| 024 | 7 |
_a10.1310/4J65-4YX1-4ET6-E5KR _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWohl, D A | |
| 245 | 0 | 0 |
_aThe safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. _h[electronic resource] |
| 260 |
_bHIV clinical trials _c |
||
| 300 |
_a136-46 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 |
_aCytomegalovirus _ximmunology |
| 650 | 0 | 4 |
_aCytomegalovirus Retinitis _xcomplications |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xcomplications |
| 650 | 0 | 4 |
_aHIV-1 _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRNA, Viral _xblood |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aSubstance Withdrawal Syndrome _ximmunology |
| 650 | 0 | 4 |
_aUveitis _xcomplications |
| 700 | 1 | _aKendall, M A | |
| 700 | 1 | _aOwens, S | |
| 700 | 1 | _aHolland, G | |
| 700 | 1 | _aNokta, M | |
| 700 | 1 | _aSpector, S A | |
| 700 | 1 | _aSchrier, R | |
| 700 | 1 | _aFiscus, S | |
| 700 | 1 | _aDavis, M | |
| 700 | 1 | _aJacobson, M A | |
| 700 | 1 | _aCurrier, J S | |
| 700 | 1 | _aSquires, K | |
| 700 | 1 | _aAlston-Smith, B | |
| 700 | 1 | _aAndersen, J | |
| 700 | 1 | _aFreeman, W R | |
| 700 | 1 | _aHiggins, M | |
| 700 | 1 | _aTorriani, F J | |
| 773 | 0 |
_tHIV clinical trials _gvol. 6 _gno. 3 _gp. 136-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1310/4J65-4YX1-4ET6-E5KR _zAvailable from publisher's website |
| 999 |
_c15822996 _d15822996 |
||